New Roche study supports use of Lucentis in wet AMD

A new study comparing Roche’s (ROG: SIX) Lucentis (ranibizumab) with the firm’s own  Avastin (bevacizumab) and Bayer's (BAYN: DE) Eylea (aflibercept) supports Lucentis as a  safe and effective therapy for the treatment of wet age-related macular degeneration (AMD).

The study, published in Clinical Ophthalmology, compares rates of endophthalmitis in wet AMD patients after intravitreal anti-VEGF injections with the products.

The analysis found that, while rates of endophthalmitis were generally low among all three agents, there were significantly higher rates among those treated with Eylea compared to Lucentis or Avastin.